CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-06-03 | Dunn Edmund Principal Accounting Officer | Sale | −2,062 | $4.45 | $9K | 23,732 |
| 2025-03-24 | Leo Chandra P. Director | Purchase | +10,000 | $5.84 | $58K | 10,000 |
| 2025-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award | +36,000 | 36,000 | ||
| 2025-01-02 | Nickson Philip Chief Business & Legal Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2025-01-02 | Dunn Edmund Principal Accounting Officer | Grant or award | +11,850 | 25,794 | ||
| 2025-01-02 | Dunn Edmund Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +53,400 | 53,400 | ||
| 2025-01-02 | Janku Filip Chief Medical Officer | Grant or award | +36,000 | 45,189 | ||
| 2025-01-02 | Janku Filip Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2025-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award | +30,000 | 30,000 | ||
| 2025-01-02 | Champoux Jennifer Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2025-01-02 | Warmuth Markus President & CEO | Grant or award | +128,000 | 544,538 | ||
| 2025-01-02 | Warmuth Markus President & CEO | Grant or award · Stock Option (Right to Buy) | +575,000 | 575,000 | ||
| 2025-01-02 | Townson Sharon Chief Scientific Officer | Grant or award | +36,000 | 36,000 | ||
| 2025-01-02 | Townson Sharon Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +161,000 | 161,000 | ||
| 2024-12-11 | Hughes Eric A Director | Grant or award · Stock Option (Right to Buy) | +44,200 | 44,200 | ||
| 2024-10-29 | Versant Venture Capital VI, L.P. 10% owner | Sale | −52,305 | $9.08 | $475K | 1,589,053 |
| 2024-10-29 | Versant Venture Capital VI, L.P. 10% owner | Sale | −15,600 | $9.41 | $147K | 1,573,453 |
| 2024-10-28 | Versant Venture Capital VI, L.P. 10% owner | Sale | −89,990 | $9.66 | $869K | 2,007,948 |
| 2024-10-28 | Versant Venture Capital VI, L.P. 10% owner | Other disposition | −1,019,867 | 4,079,469 | ||
| 2024-10-28 | Versant Venture Capital VI, L.P. 10% owner | Other acquisition | +20,397 | 20,397 |
Page 6 of 9 · 174 trades